细节化药学服务对慢阻肺患者临床疗效的影响

doi:10.3969/j.issn.1004-7115.2021.02.012

摘要/Abstract

摘要： 目的分析慢阻肺患者接受细节化药学服务对临床疗效的影响。方法选取2018年1月—2019年5月就诊的慢阻肺患者80例,根据其入院就诊单双号,予以对照研究,其中就诊单号纳入控制组;就诊双号纳入试验组。控制组仅实施常规治疗,基于此试验组加强细节化药学服务。比较两个组别入院、出院时肺功能指标(FEV1%)、呼吸困难指数(mMRC)分级、生活质量评分(CAT)等指标变化、用药依从性、不良反应率及用药差错率。结果两个组别出院时FEV1%、mMRC分级、CAT评分等对比发现试验组均优于控制组(P<0.05),差异统计学意义;但入院时二者差异无统计学意义(P>0.05)。两个组别用药依从性、不良反应率、用药差错率等对比发现试验组均优于控制组(P<0.05),差异有统计学意义。结论慢阻肺患者接受细节化药学服务的效果显著,既可改善患者呼吸状况和肺功能,又可减少不良反应和用药差错,还可提升用药依从性和生活质量,值得推广研究。

关键词: 慢阻肺患者, 细节化药学服务, 临床疗效, 影响

Abstract: Objective: To analyze the effect of detailed pharmaceutical care on clinical efficacy of patients with COPD .Methods: From January 2018 to May 2019, 80 patients with copd were selected for a controlled study based on their number of admission to hospital.Patients with even numbers were included in the experimental group.The control group only received conventional treatment, and the experimental group also received enhanced detailed pharmaceutical care besides conventional treatment.Lung function index (fev1%), respiratory distress index (mMRC) grading, quality of life score (CAT) and other indicators, medication compliance, adverse reaction rate and medication error rate were compared between the two groups at admission and discharge.Results: Fev1%, mMRC grading and CAT score of the two groups at discharge showed that the experimental group was superior to the control group (P＜0.05), which had statistical value; However, there was no significant difference between the two at the time of admission (P＞0.05).The comparison of medication compliance, adverse reaction rate and medication error rate between the two groups showed that the experimental group was superior to the control group (P＜0.05), which had statistical value.Conclusion: Detailed pharmaceutical care for patients with COPD can improve their respiratory status and lung function, reduce adverse reactions and medication errors, and improve drug compliance and quality of life. It is worthy of promotion and research.

Key words: COPD patients, detailed pharmaceutical care, clinical efficacy, impact

中图分类号:

R974

胡月凤, 周向前. 细节化药学服务对慢阻肺患者临床疗效的影响[J]. betway必威登陆网址（betway.com ）学报, 2021, 42(2): 118-120.

HU Yue-feng, ZHOU Xiang-qian. The effect of detailed pharmaceutical care on clinical efficacy of patients with copd[J]. Journal of Shandong First Medical Unversity & Shandong Academy of Medical Sciences, 2021, 42(2): 118-120.

参考文献

[1] 陈亚红.2021年GOLD慢性阻塞性肺疾病诊断、治疗及预防全球策略解读[J].中国医学前沿杂志(电子版),2021,13(01):16-37.
[2] 康芳,吴爱芬.振动排痰护理在慢阻肺患者中的应用效果评价[J].罕少疾病杂志,2021,28(01):65-66.
[3] 施静,罗勇.慢性阻塞性肺疾病频发加重表型患者危险因素分析[J/OL].临床肺科杂志,2021(02):235-239.
[4] 刘永胜.麻杏石甘汤加减治疗慢阻肺的临床疗效[J].中国城乡企业卫生,2021,36(01):168-169.
[5] 钱凤文.噻托溴铵联合布地奈德治疗慢性阻塞性肺疾病急性加重的临床疗效观察[J].吉林医学,2021,42(01):48-50.
[6] 吴苏佶,魏毅,石俊青,等.肺纤维化合并肺气肿综合征的临床特征与危险因素分析[J/OL].中国呼吸与危重监护杂志:2021,1:1-8.[2021-01-28]
[7] 胡柳柳.运动并呼吸训练在慢阻肺康复治疗中的作用及改善肺功能影响观察[J].疾病监测与控制,2021,15(01):28-31.
[8] 史会平.加味六君子汤在慢性阻塞性肺疾病稳定期的应用效果观察[J].中国中医药科技,2021,28(01):156-157.
[9] 朱国乾.吸入激素联合噻托溴铵治疗哮喘-慢阻肺重叠综合征的临床疗效评价探讨[J].数理医药学杂志,2021,34(01):84-86.
[10] 王毅,李兰,刘涛,等.序贯健肌操联合床旁B超监测膈肌预测老年慢性阻塞性肺疾病急性加重期患者机械通气撤机的临床观察[J].中国老年学杂志,2021,41(01):56-59.
[11] 何权瀛.哮喘——慢阻肺重叠综合征的诊断和治疗以及管理一事的由来和结局[J/OL].中国呼吸与危重监护杂志,2021,1:1-4[2021-01-20].
[12] 王瑾,姜志林.三联疗法治疗哮喘-慢阻肺重叠的临床疗效观察[J].吉林医药学院学报,2021,42(01):12-14.
[13] 贾长龙,鹿志军.应用运动、呼吸训练提高慢性阻塞性肺疾病患者康复治疗效果的价值研究[J].中国疗养医学,2021,30(01):82-83.
[14] 胡皖玲.秋冬应防慢阻肺来袭[J].保健医苑,2021(01):26-27.
[15] 仲芩. 带量采购持续深化如何确保慢阻肺长期治疗效果[N]. 医药经济报,2021-01-04(007).
[16] 史卉.护理干预在老年慢性阻塞性肺疾病患者护理中的效果观察[J].继续医学教育,2020,34(12):135-137.
[17] 张强.普米克令舒联合多索茶碱在慢阻肺急性加重期患者中的应用[J].内蒙古医学杂志,2020,52(12):1458-1459.
[18] 卢峥.协同护理干预对慢阻肺患者自我护理能力及预后的影响[J].内蒙古医学杂志,2020,52(12):1478-1479.
[19] 肖宝勤.延续性护理干预对慢阻肺患者肺功能及生活质量的影响[J].内蒙古医学杂志,2020,52(12):1516-1517.
[20] 张云凤,曲玲,吴颖,等.医教协同下全专联合慢阻肺管理模式[J].解放军医院管理杂志,2020,27(12):1158-1160.